The blood-brain barrier: bottleneck in brain drug development
- PMID: 15717053
- PMCID: PMC539316
- DOI: 10.1602/neurorx.2.1.3
The blood-brain barrier: bottleneck in brain drug development
Abstract
The blood-brain barrier (BBB) is formed by the brain capillary endothelium and excludes from the brain approximately 100% of large-molecule neurotherapeutics and more than 98% of all small-molecule drugs. Despite the importance of the BBB to the neurotherapeutics mission, the BBB receives insufficient attention in either academic neuroscience or industry programs. The combination of so little effort in developing solutions to the BBB problem, and the minimal BBB transport of the majority of all potential CNS drugs, leads predictably to the present situation in neurotherapeutics, which is that there are few effective treatments for the majority of CNS disorders. This situation can be reversed by an accelerated effort to develop a knowledge base in the fundamental transport properties of the BBB, and the molecular and cellular biology of the brain capillary endothelium. This provides the platform for CNS drug delivery programs, which should be developed in parallel with traditional CNS drug discovery efforts in the molecular neurosciences.
Figures
![FIG. 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/539316/bin/zne0010500570001.gif)
![FIG. 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/539316/bin/zne0010500570002.gif)
![FIG. 3.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/539316/bin/zne0010500570003.gif)
![FIG. 4.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/539316/bin/zne0010500570004.gif)
![FIG. 5.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/539316/bin/zne0010500570005.gif)
![FIG. 6.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/539316/bin/zne0010500570006.gif)
![FIG. 7.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/539316/bin/zne0010500570007.gif)
![FIG. 8.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/539316/bin/zne0010500570008.gif)
Similar articles
-
Blood-brain barrier: an impediment to neuropharmaceuticals.Clin Pharmacol Ther. 2015 Apr;97(4):308-13. doi: 10.1002/cpt.77. Epub 2015 Feb 24. Clin Pharmacol Ther. 2015. PMID: 25670372
-
Translational aspects of blood-brain barrier transport and central nervous system effects of drugs: from discovery to patients.Clin Pharmacol Ther. 2015 Apr;97(4):380-94. doi: 10.1002/cpt.76. Epub 2015 Feb 20. Clin Pharmacol Ther. 2015. PMID: 25670219 Review.
-
Alzheimer's disease drug development and the problem of the blood-brain barrier.Alzheimers Dement. 2009 Sep;5(5):427-32. doi: 10.1016/j.jalz.2009.06.003. Alzheimers Dement. 2009. PMID: 19751922 Free PMC article.
-
Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development.Pharm Res. 2007 Sep;24(9):1745-58. doi: 10.1007/s11095-007-9374-5. Epub 2007 Jul 10. Pharm Res. 2007. PMID: 17619998 Review.
-
The blood-brain barrier: clinical implications for drug delivery to the brain.J R Coll Physicians Lond. 1994 Nov-Dec;28(6):502-6. J R Coll Physicians Lond. 1994. PMID: 7884704 Free PMC article. Review.
Cited by
-
Brain Targeting Nanomedicines: Pitfalls and Promise.Int J Nanomedicine. 2024 May 27;19:4857-4875. doi: 10.2147/IJN.S454553. eCollection 2024. Int J Nanomedicine. 2024. PMID: 38828195 Free PMC article. Review.
-
Supramolecular interaction in the action of drug delivery systems.Chem Sci. 2024 Apr 30;15(21):7811-7823. doi: 10.1039/d3sc04585d. eCollection 2024 May 29. Chem Sci. 2024. PMID: 38817563 Free PMC article. Review.
-
The use of photodynamic therapy in medical practice.Front Oncol. 2024 May 8;14:1373263. doi: 10.3389/fonc.2024.1373263. eCollection 2024. Front Oncol. 2024. PMID: 38803535 Free PMC article. Review.
-
Evaluation of the Transport and Binding of Dopamine-Loaded PLGA Nanoparticles for the Treatment of Parkinson's Disease Using In Vitro Model Systems.Pharmaceutics. 2024 Apr 23;16(5):571. doi: 10.3390/pharmaceutics16050571. Pharmaceutics. 2024. PMID: 38794233 Free PMC article.
-
Dopamine- and Grape-Seed-Extract-Loaded Solid Lipid Nanoparticles: Interaction Studies between Particles and Differentiated SH-SY5Y Neuronal Cell Model of Parkinson's Disease.Molecules. 2024 Apr 13;29(8):1774. doi: 10.3390/molecules29081774. Molecules. 2024. PMID: 38675592 Free PMC article.
References
-
- Pardridge WM. Brain drug targeting: the future of brain drug development. Cambridge, UK: Cambridge University Press, 2001.
-
- Lloyd K, Hornykiewicz O. Parkinson’s disease activity of l-dopa decarboxylase in discrete brain regions. Science 170: 1212–1213, 1970. - PubMed
-
- Zivadinov R, Zorzon M, Tommasi MA, Nasuelli D, Bernardi M, Monti-Bragadin L, et al. A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon β-1a. J Neurol Sci 216: 113–118, 2003. - PubMed
-
- Antinori A, Cingolani A, Giancola ML, Forbici F, De Luca A, Perno CF. Clinical implications of HIV-1 drug resistance in the neurological compartment. Scand J Infect Dis Suppl [35 Suppl] 106: 41–44, 2003. - PubMed
-
- Kandanearatchi A, Williams B, Everall IP. Assessing the efficacy of highly active antiretroviral therapy in the brain. Brain Pathol 13: 104–110, 2003. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources